Sutherland Health (SHGP)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | 4.81 |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.56 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Mar | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | ||||||||||
FINANCIAL BRIEF: For the six months ended 30 September 2012, Sutherland Health Group plc revenues increased from L333K to L690K. Net income totaled L100K vs. loss of L43K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest Payable decrease of 27% to L13K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Sutherland Health Group plc is an investment holding company. The Company together with its subsidiaries is engaged in trading of health care products and sexual products. The Company’s products include babskin, which includes lotion, baby bath, baby shampoo, and baby changing mat, Condomania, Liquid Silk, Fluorodine Active Toothpaste, Thixo-D Original, and Thixo-D Cal-Free. During the fiscal year ended March 31, 2012 (fiscal 2012), 22 products of the Company were stocked by Amazon.co.uk. On April 17, 2012, the Company announced that it continued to develop its business with key wholesalers, such as Phoenix, AAH, and Alliance. The Company has three 100% owned subsidiaries: Sutherland Health Limited, Sexual Health Group Ltd, and Condomania PLC.
Directors: Stephen Coke (Fin. Dir.) 50,
No. of Employees: 5 No. of Shareholders: n/a
| Last Annual | March 31st, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 69,752,345 |
| Free Float | 14.6m (20.9%) |
| Sector | Consumer Defensives |
| Industry | Personal & Household Products & Services |
| Index | |
| Exchange |
ICAP Securities & Derivatives Exchange |
| Eligible for | an ISA? a SIPP? |
| Address | Unit 1 Rivermead Pipers Way, THATCHAM, RG19 4EP, United Kingdom |
| Web | http://www.sutherlandhealth.com |
| Phone | +44 1635 874488 |
| Contact | () |
| Registrar | Neville Registrars |
| Auditors | James Cowper LLP |
